FDA official logo
GSRS logoPFDA official logo

TRONTINEMAB

UNII:N0GBZ1GWC2
Formula:
Preferred Substance Name:TRONTINEMAB

  • 2568868-35-7
  • IMMUNOGLOBULIN (G1-VH-CKAPPA_VKAPPA-CH1)_(G1_KAPPA) WITH DOMAIN CROSSOVER, ANTI-(HOMO SAPIENS APP (AMYLOID BETA, A4 PRECURSOR PROTEIN) ABETA, CONFORMATIONAL EPITOPE 1-40/42)) AND ANTI- (HOMO SAPIENS TFRC (TRANSFERRIN RECEPTOR, P90, CD71)), HUMANIZED MONOCLONAL ANTIBODY, BISPECIFIC; FUSED CHAIN G1-VH-CKAPPA BISPECIFIC, ANTI-APP A BETA AND ANTI-TFRC (1-702) (GAMMA1 HEAVY CHAIN ANTI-APP ABETA (1-455) HUMANIZED (VH (HOMO SAPIENS IGHV3-23*04 (92.9%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT (8.8.19) (26-33.51-58.97-115)) (1-126) -HOMO SAPIENS IGHG1*01, G1M17,1, G1V32 CH3 W22 (CH1 K26>E (156), K119>E (222), K120 (223) (127-224), HINGE 1-15 (225-239), CH2 (240-349), CH3 S10>C (363), D12 (365), L14 (367), T22>W (375) (350-454), CHS K2>DEL (455)) (127-455)) -18-MER DIGLYCYL-SERYL-TRIS(TETRAGLYCYL-SERYL) LINKER (456-473) -VH-CKAPPA CHAIN ANTI-TFRC (474-702) HUMANIZED (VH (HOMO SAPIENS IGHV4-31*02 (76.0%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT (8.7.19) (498-505.523-529.566-584)) (474-595) -ALANYLSERYL (596-597) -C-KAPPA (HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (641), V101 (679) (598-702)), (229-215''')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI-APP ABETA (1'''-215''') HUMANIZED (V-KAPPA (HOMO SAPIENS IGKV3D-7*01 (89.6%) - IGKJ1*01 (100%), CDR-IMGT (7.3.9) (27-33.51-53.90-98)) (1'''-108''') - HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (154), V101 (192), E12>R (124), Q13>K (125) (109'''-215''')), (702-215'''')-DISULFIDE WITH VKAPPA- CH1 CHAIN ANTI-TFRC (1''''-215'''') HUMANIZED (V-KAPPA (HOMO SAPIENS IGKV1-13*02 (94.4%) -IGKJ4*01 (100%), CDR-IMGT (6.3.12) (27- 32.50-52.89-100)) (1''''-110'''') -DISERYL (111''''-112'''') -CH1-HINGE (HOMO SAPIENS IGHG1*01 CH1-H, G1M17 (CH1 K120 (209) (113''''-210''''), HINGE 1-5 (211''''-215'''')) (113''''-215'''')), GAMMA1 HEAVY CHAIN ANTI-APP ABETA (1''-456'') HUMANIZED (VH (HOMO SAPIENS IGHV3-23*04 (92.9%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT (8.8.19) (26-33.51-58.97-115)) (1''-126'') -HOMO SAPIENS IGHG1*01, G1M17,1, G1V33 CH3 S22, A24, V86 (CH1 K26>E (156), K119>E (222), K120 (223) (127''-224''), HINGE 1-15 (225''-239''), CH2 (240''- 349''), CH3 Y5>C (358), D12 (365), L14 (367), T22>S (375), L24>A (377), Y86>V (416) (350''-454''), CHS (455''-456'')) (127''-456'')), (229''- 215''')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI-APP ABETA (1'''-215''') HUMANIZED (V-KAPPA (HOMO SAPIENS IGKV3D-7*01 (89.6%) - IGKJ1*01 (100%), CDR-IMGT (7.3.9) (27-33.51-53.90-98)) (1'''-108''') - HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (154), V101 (192) (109'''- 215''')), DIMER (235-235'':238-238'':363-358'')-TRISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA
  • IMMUNOGLOBULIN G1 (156-GLUTAMIC ACID,222-GLUTAMIC ACID,363-CYSTEINE,375-TRYPTOPHAN,DE-456-LYSINE), ANTI-(HUMAN .BETA.-AMYLOID 1-40/42) (HUMAN CLONE MAB31 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGS(GGGGS)3) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN TRANSFERRIN RECEPTOR 1) (HUMAN-ORYCTOLAGUS CUNICULUS CLONE BBB-1026 HEAVY CHAIN V-D-J REGION) FUSION PROTEIN WITH IMMUNOGLOBULIN (1-ALANINE,2-SERINE) (HUMAN .KAPPA.-CHAIN C REGION), DISULFIDE WITH IMMUNOGLOBULIN (ENDO-111-SERINE,ENDO-112-SERINE) ANTI-(HUMAN TRANSFERRIN RECEPTOR 1) (HUMAN-ORYCTOLAGUS CUNICULUS CLONE BBB-1026 .KAPPA.-CHAIN V-J REGION) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN CH1 REGION), (235->235'),(238->238'),(358->363')- TRIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (156-GLUTAMIC ACID,222-GLUTAMIC ACID,358-CYSTEINE,375-SERINE,377-ALANINE,416-VALINE) ANTI-(HUMAN .BETA.-AMYLOID 1-40/42) (HUMAN CLONE MAB31 .GAMMA.1-CHAIN), DISULFIDE WITH IMMUNOGLOBULIN G1 (124-ARGININE,125-LYSINE) ANTI-(HUMAN .BETA.-AMYLOID 1-40/42) (HUMAN CLONE MAB31 .KAPPA.-CHAIN)
  • RECOMBINANT (2+1) BISPECIFIC HUMANIZED MONOCLONAL ANTI-A-BETA PEPTIDE AND BINDS TO TRANSFERRIN RECEPTOR (TFR).
  • RG6102
  • RG-6102
  • RO7126209
  • RO-7126209
  • TRONTINEMAB [INN]
  • TRONTINEMAB [USAN]




UNII - N0GBZ1GWC2 | UNII Search Service